Literature DB >> 7207345

Phototherapy of human tumours using haematoporphyrin derivative.

I J Forbes, P A Cowled, A S Leong, A D Ward, R B Black, A J Blake, F J Jacka.   

Abstract

Photoradiation therapy (phototherapy) is a recently introduced treatment for malignant tumours, which depends on the activation of a photoreactive drug selectively localized to tumours. An experience in 27 patients with haematoporphyrin derivative is described. The haematoporphyrin derivative was activated by light of 630-nm wavelength, which was delivered to cutaneous tumours from a specially designed incandescent lamp and to deep tumours through a quartz fibre from a laser system. Tumours were eradicated in five patients and incomplete tumour destruction was observed in 14 others. The only significant side effect was temporary cutaneous photosensitivity. This form of treatment has considerable potential, particularly when other treatments have either failed or cannot be applied. However, it is premature to formulate indications for its use. Rapid technological developments can be anticipated which will greatly enhance the efficacy of photodynamic destruction of tumours.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7207345     DOI: 10.5694/j.1326-5377.1980.tb100708.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  17 in total

1.  Response of human endometrium and ovarian carcinoma cell-lines to photodynamic therapy.

Authors:  G H Raab; A F Schneider; W Eiermann; H Gottschalk-Deponte; R Baumgartner; W Beyer
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  Photodynamic therapy of esophageal carcinoma.

Authors:  T Okunaka; H Kato; C Conaka; H Yamamoto; A Bonaminio; M L Eckhauser
Journal:  Surg Endosc       Date:  1990       Impact factor: 4.584

Review 3.  Phototherapy in tumors.

Authors:  S G Bown
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

4.  Observations in studies of quantitative kinetics of tritium labelled hematoporphyrin derivatives (HpDI and HpDII) in the normal and neoplastic rat brain model.

Authors:  F M Little; C J Gomer; S Hyman; M L Apuzzo
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

5.  Photoradiation therapy of 9L-gliosarcoma in rats: hematoporphyrin derivative (types I and II) followed by laser energy.

Authors:  M K Cheng; J McKean; B Mielke; J Tulip; D Boisvert
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

6.  Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity.

Authors:  R M Böhmer; K Hoffmann; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Penetration of hematoporphyrin derivative into rat brain and intracerebral 9L glioma tissue.

Authors:  D P Boisvert; J D McKean; J Tulip; J Cummins; M K Cheng
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  High-dose photoirradiation of esophageal cancer.

Authors:  R J Thomas; M Abbott; P S Bhathal; D J St John; G Morstyn
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

9.  Laser therapy in 100 tracheobronchial tumours.

Authors:  M R Hetzel; C Nixon; W M Edmondstone; D M Mitchell; F J Millard; E M Nanson; A A Woodcock; C E Bridges; A M Humberstone
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

10.  Modification by vasoactive drugs of tumour destruction by photodynamic therapy with haematoporphyrin derivative.

Authors:  P A Cowled; I J Forbes
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.